Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
2.
Blood ; 130(26): 2860-2871, 2017 12 28.
Article in English | MEDLINE | ID: mdl-29138221

ABSTRACT

The BCR-ABL specific tyrosine kinase inhibitors (TKI) changed the outcome of chronic myeloid leukemia (CML), turning a life-threatening disease into a chronic illness. However, TKI are not yet curative, because most patients retain leukemic stem cells (LSC) and their progenitors in bone marrow and relapse following treatment cessation. At diagnosis, deregulation of the bone morphogenetic protein (BMP) pathway is involved in LSC and progenitor expansion. Here, we report that BMP pathway alterations persist in TKI-resistant patients. In comparison with patients in complete cytogenetic remission, TKI-resistant LSC and progenitors display high levels of BMPR1b expression and alterations of its cellular localization. In vitro treatment of immature chronic phase CML cells with TKI alone, or in combination with interferon-α, results in the preferential survival of BMPR1b+ cells. We demonstrated persistent and increasing BMP4 production by patients' mesenchymal cells with resistance. Patient follow-up revealed an increase of BMPR1b expression and in BMP4 expression in LSC from TKI-resistant patients in comparison with diagnosis, while remaining unchanged in sensitive patients. Both leukemic and nonleukemic cells exhibit higher BMP4 levels in the bone marrow of TKI-resistant patients. Exposure to BMP2/BMP4 does not alter BCR-ABL transcript expression but is accompanied by the overexpression of TWIST-1, a transcription factor highly expressed in resistant LSC. By modulating BMP4 or BMPR1b expression, we show that these elements are involved in TKI resistance. In summary, we reveal that persistence of BMP alterations and existence of an autocrine loop promote CML-primitive cells' TKI resistance.


Subject(s)
Autocrine Communication , Bone Morphogenetic Proteins/metabolism , Drug Resistance, Neoplasm , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Protein Kinase Inhibitors/therapeutic use , Bone Morphogenetic Protein 4/analysis , Bone Morphogenetic Protein 4/metabolism , Bone Morphogenetic Protein Receptors, Type I/analysis , Bone Morphogenetic Protein Receptors, Type I/metabolism , Bone Morphogenetic Proteins/analysis , Humans , Neoplastic Stem Cells/metabolism , Nuclear Proteins/analysis , Nuclear Proteins/metabolism , Protein Binding , Protein Kinase Inhibitors/pharmacology , Protein-Tyrosine Kinases/antagonists & inhibitors , Twist-Related Protein 1/analysis , Twist-Related Protein 1/metabolism
3.
Gastroenterology ; 153(2): 470-479.e4, 2017 08.
Article in English | MEDLINE | ID: mdl-28512021

ABSTRACT

BACKGROUND & AIMS: Statin use has been associated with a reduced incidence of colorectal cancer and might also affect survival of patients diagnosed with colon cancer. Statins are believed to inhibit Ras signaling and may also activate the bone morphogenetic protein (BMP) signaling pathway in colorectal cancer cells. We investigated the effects of statins on overall survival of patients with a diagnosis of colon cancer, and whether their effects were associated with changes in KRAS or the BMP signaling pathways. METHODS: Data were derived from the PHARMO database network (Netherlands) and linked to patients diagnosed with colon cancer from 2002 through 2007, listed in the Eindhoven Cancer Registry. We obtained information on causes of death from statistics Netherlands. We constructed a tissue microarray of 999 colon cancer specimens from patients who underwent surgical resection from 2002 through 2008. Survival was analyzed with statin user status after diagnosis as a time-dependent covariate. Multivariable Poisson regression survival models and Cox analyses were used to study the effect of statins on survival. Tumor tissues were analyzed by immunohistochemistry for levels of SMAD4, BMPR1A, BMPR1B, and BMPR2 proteins. Tumor tissues were considered to have intact BMP signaling if they contained SMAD4 plus BMPR1A, BMPR1B, or BMPR2. DNA was isolated from tumor tissues and analyzed by quantitative polymerase chain reaction to detect mutations in KRAS. The primary outcome measures were overall mortality and cancer-specific mortality. RESULTS: In this cohort, 21.0% of the patients (210/999) were defined as statin users after diagnosis of colon cancer. Statin use after diagnosis was significantly associated with reduced risk of death from any cause (adjusted relative risk [RR], 0.67; 95% confidence interval [CI], 0.51-0.87; P = .003) and death from cancer (adjusted RR, 0.66; 95% CI, 0.49-0.89; P = .007). Statin use after diagnosis was associated with reduced risk of death from any cause or from cancer for patients whose tumors had intact BMP signaling (adjusted RR, 0.39; 95% CI, 0.22-0.68; P = .001), but not for patients whose tumors did not have BMP signaling (adjusted RR, 0.81; 95% CI, 0.55-1.21; P = .106; P < .0001 for the interaction). Statin use after diagnosis was not associated with reduced risk of death from any cause or from cancer for patients whose tumors did not contain KRAS mutations (adjusted RR, 0.81; 95% CI, 0.56-1.18; P = .273) or whose tumors did have KRAS mutations (adjusted RR, 0.59; 95% CI 0.35-1.03; P = .062; P = .90 for the interaction). CONCLUSIONS: In an analysis of 999 patients with a diagnosis of colon cancer, we associated statin with reduced risk of death from any cause or from cancer. The benefit of statin use is greater for patients whose tumors have intact BMP signaling, independent of KRAS mutation status. Randomized controlled trials are required to confirm these results.


Subject(s)
Colonic Neoplasms/drug therapy , Colonic Neoplasms/mortality , Hydroxymethylglutaryl CoA Reductases/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Aged , Bone Morphogenetic Protein Receptors, Type I/analysis , Bone Morphogenetic Protein Receptors, Type II/analysis , Colonic Neoplasms/pathology , DNA/isolation & purification , Female , Follow-Up Studies , Humans , Male , Microarray Analysis , Middle Aged , Multivariate Analysis , Mutation/drug effects , Netherlands , Poisson Distribution , Proportional Hazards Models , Proto-Oncogene Proteins p21(ras)/genetics , Real-Time Polymerase Chain Reaction , Registries , Retrospective Studies , Signal Transduction/drug effects , Smad4 Protein/analysis
4.
Domest Anim Endocrinol ; 58: 126-133, 2017 01.
Article in English | MEDLINE | ID: mdl-26542941

ABSTRACT

The purpose of this study was to investigate the expression of bone morphogenetic protein 4 (BMP4) and its receptors, bone morphogenetic protein receptor I (BMPRI) and BMPRII, in the pituitary gland of healthy adult dogs and in those with ACTH-secreting pituitary adenoma. Quantitative polymerase chain reaction analysis showed that the BMP4 messenger RNA expression level in the ACTH-secreting pituitary adenoma samples was significantly lower than that in the normal pituitary gland samples (P = 0.03). However, there were no statistically significant differences between samples with respect to the messenger RNA expression levels of the receptors BMPRIA, BMPRIB, and BMPRII. Double-immunofluorescence analysis of the normal canine pituitary showed that BMP4 was localized in the thyrotroph (51.3 ± 7.3%) and not the corticotroph cells. By contrast, BMPRII was widely expressed in the thyrotroph (19.9 ± 5.2%) and somatotroph cells (94.7 ± 3.6%) but not in the corticotroph cells (P < 0.001, thyrotroph cells vs somatotroph cells). Similarly, in ACTH-secreting pituitary adenoma, BMP4 and BMPRII were not expressed in the corticotroph cells. Moreover, the percentage of BMP4-positive cells was also significantly reduced in the thyrotroph cells of the surrounding normal pituitary tissue obtained from the resected ACTH-secreting pituitary adenoma (8.3 ± 7.9%) compared with that in normal canine pituitary (P < 0.001). BMP4 has been reported to be expressed in corticotroph cells in the human pituitary gland. Therefore, the results of this study reveal a difference in the cellular pattern of BMP4-positive staining in the pituitary gland between humans and dogs and further revealed the pattern of BMPRII-positive staining in the dog pituitary gland. These species-specific differences regarding BMP4 should be considered when using dogs as an animal model for Cushing's disease.


Subject(s)
ACTH-Secreting Pituitary Adenoma/veterinary , Bone Morphogenetic Protein 4/genetics , Dog Diseases/metabolism , Gene Expression , Pituitary Gland/metabolism , ACTH-Secreting Pituitary Adenoma/chemistry , ACTH-Secreting Pituitary Adenoma/metabolism , Animals , Bone Morphogenetic Protein 4/analysis , Bone Morphogenetic Protein Receptors, Type I/analysis , Bone Morphogenetic Protein Receptors, Type I/genetics , Bone Morphogenetic Protein Receptors, Type II/analysis , Bone Morphogenetic Protein Receptors, Type II/genetics , Corticotrophs/chemistry , Disease Models, Animal , Dogs , Female , Fluorescent Antibody Technique/veterinary , Humans , Male , Pituitary ACTH Hypersecretion , Pituitary Gland/chemistry , RNA, Messenger/analysis , Thyrotrophs/chemistry
5.
Br J Oral Maxillofac Surg ; 53(2): 158-63, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25480012

ABSTRACT

We investigated the effects of recombinant human bone morphogenetic protein-7 (rhBMP-7) on the behaviour of oral keratinocytes and head and neck squamous cell carcinoma (SCC) cells in vitro. Expression of all three BMP receptors was high (p<0.01), and rhBMP-7 exhibited significant dose-related inhibitory effects on the doubling time and viability of cancer cells (p<0.01), but not on the proliferation or viability of oral keratinocytes. It elicited no significant effect on the invasion of Matrigel in SCC of the head and neck. Results indicate that in cell culture, rhBMP-7 exerts antineoplastic effects. This should be tested in an orthotopic animal model to more closely replicate in vivo effects.


Subject(s)
Antineoplastic Agents/pharmacology , Bone Morphogenetic Protein 7/pharmacology , Carcinoma, Squamous Cell/pathology , Keratinocytes/drug effects , Mouth Neoplasms/pathology , Bone Morphogenetic Protein Receptors, Type I/analysis , Bone Morphogenetic Protein Receptors, Type II/analysis , Cell Culture Techniques , Cell Death/drug effects , Cell Line , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Cellular Senescence/drug effects , Culture Media, Serum-Free , Humans , Indicators and Reagents , Neoplasm Invasiveness , Nitrophenols , Organophosphorus Compounds
6.
Int J Clin Exp Pathol ; 7(5): 2312-8, 2014.
Article in English | MEDLINE | ID: mdl-24966941

ABSTRACT

Hirschsprung disease (HSCR) is characterized by the absence of intramural ganglion cells in the nerve plexuses of the distal gut. Recent studies have shown that the bone morphogenetic protein receptor-type IA (BMPR1α), actinin-alpha 4 (ACTN4α) and fatty acid binding protein 7 (FABP7) play important roles in the differentiation and development of neurons. The aganglionic (stenotic) and the ganglionic (normal) colon segment tissues of 60 HSCR patients were collected to investigate the expression pattern of BMPR1α, ACTININ-4α and FABP7 using RT-PCR, quantitative real-time RT-PCR (qRT-PCR) and immunohistochemical staining. The mRNA and protein expressions of BMPR1α and ACTN4α were higher in the stenotic colon segment tissue than those in the normal colon segment tissue. However, the mRNA and protein expressions of FABP7 were lower in the stenotic colon segment tissue than those in the normal colon segment tissue. The study in HSCR patients, findings in mRNA and protein alterations to expecting provide more information to in order to find some clue for the pathomechanism of HSCR disease.


Subject(s)
Actinin/analysis , Bone Morphogenetic Protein Receptors, Type I/analysis , Carrier Proteins/analysis , Colon/chemistry , Hirschsprung Disease/metabolism , Tumor Suppressor Proteins/analysis , Actinin/genetics , Biopsy , Bone Morphogenetic Protein Receptors, Type I/genetics , Carrier Proteins/genetics , Child, Preschool , Colon/pathology , Constriction, Pathologic , Fatty Acid-Binding Protein 7 , Female , Gene Expression Regulation , Hirschsprung Disease/genetics , Hirschsprung Disease/pathology , Humans , Immunohistochemistry , Infant , Male , RNA, Messenger/analysis , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Tumor Suppressor Proteins/genetics
7.
Protein J ; 30(2): 138-42, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21327720

ABSTRACT

Hirschsprung's disease (HSCR) is the most common identifiable developmental disorder of the enteric nervous system. The present study was designed to analyze the differential proteomic patterns in stenotic colon segment tissues from patients with HSCR. We analyzed 20 paired stenotic and normal colon segment tissues from patients with HSCR, and identified 13 proteins from stenotic segment tissues peptide fingerprint mapping and SELDI MS that were separated using 2-DE. The protein levels of four selected proteins (α-actinin-4, ACTN4; myosin regulatory light chain interacting protein, MYLIP; fatty acid binding protein 7, FABP7; bone morphogenetic protein receptor type 1A, BMPR1A) were further validated by Western blot analysis. This study, investigating for the first time proteomic changes in stenotic colon segment tissues from patients with HSCR, provides potential markers or promising new candidate actors for the pathogenesis of HSCR.


Subject(s)
Colon/metabolism , Hirschsprung Disease/metabolism , Proteome/metabolism , Actinin/analysis , Actinin/biosynthesis , Adolescent , Amino Acid Sequence , Biomarkers/analysis , Biomarkers/metabolism , Bone Morphogenetic Protein Receptors, Type I/analysis , Bone Morphogenetic Protein Receptors, Type I/biosynthesis , Carrier Proteins/analysis , Carrier Proteins/biosynthesis , Child , Child, Preschool , Colon/pathology , Constriction, Pathologic/diagnosis , Constriction, Pathologic/metabolism , Constriction, Pathologic/pathology , Fatty Acid-Binding Protein 7 , Hirschsprung Disease/diagnosis , Hirschsprung Disease/pathology , Humans , Infant , Molecular Sequence Data , Proteome/analysis , Proteomics , Tumor Suppressor Proteins/analysis , Tumor Suppressor Proteins/biosynthesis , Ubiquitin-Protein Ligases/analysis , Ubiquitin-Protein Ligases/biosynthesis
8.
J Dent Res ; 89(6): 603-8, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20351355

ABSTRACT

It is known that stem cells from exfoliated deciduous teeth (SHED) can be induced to differentiate into odontoblasts. However, the nature of dentin-derived morphogenic signals required for dental pulp stem cell differentiation remains unclear. The hypothesis underlying this work is that dentin-derived Bone Morphogenetic Proteins (BMP) are necessary for the differentiation of SHED into odontoblasts. We observed that SHED express markers of odontoblastic differentiation (DSPP, DMP-1, MEPE) when seeded in human tooth slice/scaffolds and cultured in vitro, or implanted subcutaneously into immunodeficient mice. In contrast, SHED cultured in deproteinized tooth slice/scaffolds, or scaffolds without a tooth slice, do not express these markers. SHED express the BMP receptors BMPR-IA, BMPR-IB, and BMPR-II. Notably, blockade of BMP-2 signaling inhibited the expression of markers of odontoblastic differentiation by SHED cultured in tooth slice/scaffolds. Collectively, this work demonstrates that dentin-derived BMP-2 is required to induce the differentiation of SHED into odontoblasts.


Subject(s)
Bone Morphogenetic Protein 2/pharmacology , Dentin/enzymology , Odontoblasts/drug effects , Animals , Antibodies, Neutralizing/pharmacology , Biomarkers/analysis , Blotting, Western , Bone Morphogenetic Protein 2/antagonists & inhibitors , Bone Morphogenetic Protein 7/antagonists & inhibitors , Bone Morphogenetic Protein 7/pharmacology , Bone Morphogenetic Protein Receptors, Type I/analysis , Bone Morphogenetic Protein Receptors, Type II/analysis , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cells, Cultured , Dental Pulp/cytology , Extracellular Matrix Proteins/analysis , Glycoproteins/analysis , Humans , Mice , Mice, SCID , Phosphoproteins/analysis , Reverse Transcriptase Polymerase Chain Reaction , Sialoglycoproteins/analysis , Signal Transduction/drug effects , Stem Cells/drug effects , Stem Cells/physiology , Subcutaneous Tissue/surgery , Tissue Scaffolds , Tooth, Deciduous/cytology
9.
Oncol Res ; 17(11-12): 601-12, 2009.
Article in English | MEDLINE | ID: mdl-19806791

ABSTRACT

Metastasis is a complex, multistep process by which a cancer cell leaves the primary tumor, travels to a distant site via the circulatory system, and establishes a secondary cancer. A deeper understanding of the molecular events underlying metastasis will provide information that will be useful for the development of new diagnostic and therapeutic strategies. The B16 and B16F10 mouse melanoma cell lines are widely used as model system for studying many aspects of cancer biology including metastasis. Compared with B16, which has a low metastatic potential, the highly metastatic cell line B16F10 displayed a higher metastatic ability along with higher expression levels of the metastasis-associated phosphatase of regenerating liver-3 (PRL-3). B16 cells transfected with PRL-3 cDNA (B16-PRL3) had metastatic abilities comparable to those of Bl16F10 cells. To study the molecular mechanisms that underlie metastasis, the proteomes of the B16, B16F10, and B16-PRL3 cell lines were compared using two-dimensional differential in-gel electrophoresis. Proteins that varied significantly in levels between these cell lines were selected and identified using mass spectrometry. Interestingly, many proteins, especially those present in membrane fractions, were similarly up- or downregulated in both the Bl16F10 and B16-PRL3 cells lines compared to B16 cell lines. The list of similarly regulated proteins included heat shock protein 70, fascin-1, septin-6, ATP synthase beta subunit, and bone morphogenic protein receptor type IB. These proteins may play a causal role in PRL-3-mediated metastasis. These investigations open an avenue for the further characterization of the molecular mechanisms that underlie metastasis.


Subject(s)
Immediate-Early Proteins/analysis , Melanoma, Experimental/chemistry , Protein Tyrosine Phosphatases/analysis , Proteomics , Animals , Bone Morphogenetic Protein Receptors, Type I/analysis , Cell Line, Tumor , Cell Movement , Electrophoresis, Gel, Two-Dimensional , HSP70 Heat-Shock Proteins/analysis , Immediate-Early Proteins/genetics , Melanoma, Experimental/pathology , Melanoma, Experimental/secondary , Mice , Protein Tyrosine Phosphatases/genetics , Proton-Translocating ATPases/analysis , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
10.
Acta Orthop Belg ; 75(1): 94-102, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19358406

ABSTRACT

A murine distraction osteogenesis model was standardized to allow analysis of the molecular pathways associated with postnatal de novo bone formation. The authors examined the presence and expression of Bone Morphogenetic Proteins (BMPs) -2, -3, -4, -6 and -7, and the BMP receptors Alk3 and Alk6 at different stages. Strong signals were detected for BMP-4 at the end of the distraction period and for BMP-6 during the entire experimental period. Signals for BMP-7 (Osteogenic Protein-1) were very low, suggesting a less important role during the normal process of distraction bone healing. Immunohistochemical staining revealed the presence of BMP-4 in the early chondroblasts, while BMP-6 was detected in the more mature cartilage cells. The data indicate a BMP molecular profile reminiscent of the embryonic maturation process in endochondral bone formation.


Subject(s)
Bone Morphogenetic Proteins/analysis , Bone Morphogenetic Proteins/physiology , Osteogenesis, Distraction , Animals , Bone Morphogenetic Protein 4/analysis , Bone Morphogenetic Protein 6/analysis , Bone Morphogenetic Protein 7/analysis , Bone Morphogenetic Protein Receptors, Type I/analysis , Immunohistochemistry , In Situ Hybridization , Male , Mice , Models, Animal , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/physiology
11.
Breast Cancer Res Treat ; 103(2): 239-46, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17004110

ABSTRACT

Bone morphogenetic proteins (BMPs) regulate diverse cellular processes, such as proliferation, differentiation, and apoptosis. The BMPs have been studied in several cancers, but thus far contradictory results have been obtained and, especially in breast cancer, information on BMPs is still limited. We performed a systematic expression survey of BMPs and their receptors in breast cancer. mRNA expression was studied of seven BMP ligands (BMP2-BMP8) and six receptors (ACVR1, BMPR1A, BMPR1B, BMPR2, ACVR2A, and ACVR2B) that specifically mediate BMP signals. Expression levels were determined in 22 breast cancer cell lines, 39 primary breast tumors, normal human mammary epithelial cell line, and normal mammary gland using semiquantitative RT-PCR. The expression frequencies and expression levels of different BMPs varied considerably in breast cancer with BMP4 and BMP7 being most frequently expressed and showing highest expression levels. The BMP specific receptors were more uniformly expressed and indicated that breast cancer is fully capable of transmitting BMP signals. Expression frequencies and levels for both the ligands and the receptors were in good concordance between the breast cancer cell lines and primary tumors. We can conclude that breast cancers possess functional BMP signaling machinery on the cell surface with distinct differences in the expression of various BMP ligands. Our survey focuses the attention particularly toward BMP4 and BMP7 and suggests their importance in breast cancer. Breast cancer cell lines and the data generated here serve as a good resource for further studies on BMP function in breast cancer.


Subject(s)
Bone Morphogenetic Proteins/genetics , Breast Neoplasms/metabolism , Transforming Growth Factor beta/genetics , Bone Morphogenetic Protein 4 , Bone Morphogenetic Protein 7 , Bone Morphogenetic Protein Receptors, Type I/analysis , Bone Morphogenetic Protein Receptors, Type II/analysis , Breast/metabolism , Female , Humans , RNA, Messenger/analysis , Signal Transduction
12.
J Pathol ; 209(2): 190-7, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16550632

ABSTRACT

Morphogens regulate epithelial cell fate decisions in the adult gastrointestinal tract. The authors hypothesized that influx of inflammatory cells into the lamina propria may disturb the normal expression gradients of morphogens (morphogenetic landscape) in gastrointestinal epithelia. Changes in the activity of the bone morphogenetic protein (BMP) pathway in normal and Helicobacter pylori-infected gastric mucosa were therefore examined. It is shown that BMP receptors, the activated (phosphorylated) form of the intracellular BMP signal transduction protein SMAD1, and BMP target ID2 all localize to gastric epithelial cells that are at the end of the axis of epithelial renewal in normal mucosa. Colonization of human gastric mucosa with H. pylori was associated with an increase in BMP2 expression due to influx of inflammatory cells that produce BMP2. Furthermore, whereas no BMP4 was detected in the normal antrum, focal infiltrates of BMP4-expressing cells were found in the H. pylori-infected stomach. This influx of BMP-expressing cells was associated with an increase in epithelial BMP signalling. Interestingly, a shift in activity of the BMP pathway was observed towards the precursor cell compartment (isthmus) of the gastric units. Thus, H. pylori infection results in an influx of inflammatory cells that disturb the normal activity gradient of a morphogenetic pathway with an established role in epithelial cell fate regulation. The data suggest that morphological changes in epithelial histology may result from alterations in the morphogenetic landscape secondary to changes in the cellular composition of the lamina propria.


Subject(s)
Bone Morphogenetic Proteins/metabolism , Helicobacter Infections/metabolism , Helicobacter pylori , Signal Transduction/physiology , Stomach Diseases/metabolism , Bone Morphogenetic Protein 2 , Bone Morphogenetic Protein 4 , Bone Morphogenetic Protein Receptors, Type I/analysis , Bone Morphogenetic Proteins/analysis , Cell Count , Epithelial Cells/metabolism , Gastric Mucosa/metabolism , Gastric Mucosa/microbiology , Humans , Immunohistochemistry/methods , Inhibitor of Differentiation Protein 2/metabolism , Smad1 Protein/metabolism , Transforming Growth Factor beta/analysis
13.
Oral Dis ; 12(2): 163-70, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16476038

ABSTRACT

OBJECTIVE: To further clarify the roles of regulators of embryonic development, bone morphogenetic protein (BMPs) and their associated molecules, in oncogenesis and cytodifferentiation of odontogenic tumors, the expression of these regulator molecules were analyzed in epithelial odontogenic tumors as well as in tooth germs. MATERIALS AND METHODS: Tooth germs, ameloblastomas, adenomatoid odontogenic tumors, and malignant ameloblastomas were examined by RT-PCR and immunohistochemistry for detection of BMP-2, -4, -7, BMP receptors I and II (BMPR-I, BMPR-II), core-binding factor alpha1 (CBFA1), and osterix. RESULTS: mRNA expression of BMPs, BMPRs, CBFA1, and osterix was detected in all odontogenic tissues. Immunohistochemical reactivity for BMPs, BMPRs, and CBFA1 was detected in both epithelial and mesenchymal cells of tooth germs and epithelial odontogenic tumors. BMPs and BMPRs were evidently expressed in odontogenic epithelial cells in tooth germs and epithelial odontogenic tumors. Acanthomatous ameloblastomas showed increased BMP-7 reactivity in keratinizing cells. Nuclear CBFA1 expression was detected scatteredly in odontogenic epithelial cells in normal and neoplastic odontogenic tissues, as well as in some mesenchymal cells in tooth germs and in some stromal cells in epithelial odontogenic tumors. Ameloblastic carcinomas showed low reactivity for BMPs, BMPRs, and CBFA1. CONCLUSION: BMPs and their associated molecules might play a role in cytodifferentiation of normal and neoplastic odontogenic epithelium via epithelial-mesenchymal interactions.


Subject(s)
Ameloblastoma/pathology , Bone Morphogenetic Proteins/analysis , Odontogenic Tumors/pathology , Bone Morphogenetic Protein 2 , Bone Morphogenetic Protein 4 , Bone Morphogenetic Protein 7 , Bone Morphogenetic Protein Receptors, Type I/analysis , Bone Morphogenetic Protein Receptors, Type II/analysis , Cell Differentiation , Cell Nucleus/ultrastructure , Cell Transformation, Neoplastic/pathology , Core Binding Factor Alpha 1 Subunit/analysis , Epithelial Cells/pathology , Epithelium/pathology , Humans , Immunohistochemistry , Mesoderm/pathology , Reverse Transcriptase Polymerase Chain Reaction , Sp7 Transcription Factor , Stromal Cells/pathology , Tooth Germ/pathology , Transcription Factors/analysis , Transforming Growth Factor beta/analysis
14.
Biol Reprod ; 74(6): 1073-82, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16436528

ABSTRACT

Bone morphogenetic proteins (BMPs) play critical roles in folliculogenesis by modulating the actions of follicle-stimulating hormone (FSH) in the ovary. However, the effects of FSH on the BMP system remain unknown. Here, we have investigated the effects of FSH on BMP signaling using the human granulosa-like tumor cell line KGN. KGN cells express BMP type I and type II receptors and the BMP signaling molecules SMADs. FSH administration upregulated BMP type IA (BMPR1A) and IB (BMPR1B) receptors, activin type II receptor (ACVR2), and BMP type II receptor (BMPR2). FSH also augmented SMAD1 and SMAD5 expression, and conversely, FSH suppressed the expression of the inhibitory SMADs, SMAD6 and SMAD7. Bioassays revealed that FSH enhances BMP-induced SMAD1/5/8 phosphorylation and cellular DNA synthesis induced by BMP6 and BMP7. Since overexpression of BMPR1A and BMPR1B, but not SMADs, significantly enhanced the BMP responses, these type I receptors were revealed to be limiting factors for BMP signaling in KGN cells. BMPs significantly suppressed progesterone synthesis induced by forskolin and dibutyryl-cAMP (BtcAMP) but had no effect on estradiol induced by the same factors. KGN cAMP levels induced by forskolin were not altered by BMPs, suggesting that BMPs regulate steroidogenesis at a level downstream of cAMP synthesis in KGN cells. In this regard, BMPs specifically reduced the STAR transcription, whereas the levels of CYP11A, HSD3B2, and CYP19 stimulated by forskolin as well as BtcAMP were not altered. Collectively, the two major factors, FSH-cAMP pathway and BMP system, are reciprocally and functionally linked. Given that BMPs downregulate FSH receptors in KGN cells, this interaction may contribute to fine-tuning of the mutual sensitivity toward BMP ligands and FSH.


Subject(s)
Bone Morphogenetic Proteins/physiology , Follicle Stimulating Hormone/physiology , Granulosa Cells/physiology , Signal Transduction/physiology , Bone Morphogenetic Protein Receptors, Type I/analysis , Bone Morphogenetic Protein Receptors, Type I/genetics , Bone Morphogenetic Protein Receptors, Type I/physiology , Bone Morphogenetic Protein Receptors, Type II/analysis , Bone Morphogenetic Protein Receptors, Type II/genetics , Bone Morphogenetic Protein Receptors, Type II/physiology , Bone Morphogenetic Proteins/analysis , Bone Morphogenetic Proteins/genetics , Bucladesine/pharmacology , Cell Differentiation/physiology , Cell Line, Tumor , Cell Proliferation , Colforsin/pharmacology , Cyclic AMP/analysis , Cyclic AMP/genetics , Cyclic AMP/physiology , Female , Follicle Stimulating Hormone/analysis , Follicle Stimulating Hormone/pharmacology , Gene Expression Regulation, Neoplastic/drug effects , Gene Expression Regulation, Neoplastic/physiology , Granulosa Cells/chemistry , Granulosa Cells/pathology , Humans , Phosphoproteins/analysis , Phosphoproteins/genetics , Phosphoproteins/physiology , Progesterone/metabolism , Receptors, FSH/analysis , Receptors, FSH/genetics , Receptors, FSH/physiology , Signal Transduction/drug effects , Signal Transduction/genetics , Smad Proteins/analysis , Smad Proteins/genetics , Smad Proteins/physiology
15.
Proc Natl Acad Sci U S A ; 102(45): 16421-5, 2005 Nov 08.
Article in English | MEDLINE | ID: mdl-16260730

ABSTRACT

The survival of motor neurons is controlled by multiple factors that regulate different aspects of their physiology. The identification of these factors is important because of their relationship to motor neuron disease. We investigate here whether Mullerian Inhibiting Substance (MIS) is a motor neuron survival factor. We find that motor neurons from adult mice synthesize MIS and express its receptors, suggesting that mature motor neurons use MIS in an autocrine fashion or as a way to communicate with each other. MIS was observed to support the survival and differentiation of embryonic motor neurons in vitro. During development, male-specific MIS may have a hormone effect because the blood-brain barrier has yet to form, raising the possibility that MIS participates in generating sex-specific differences in motor neurons.


Subject(s)
Glycoproteins/physiology , Motor Neurons/physiology , Testicular Hormones/physiology , Animals , Anti-Mullerian Hormone , Bone Morphogenetic Protein Receptors, Type I/analysis , Bone Morphogenetic Protein Receptors, Type I/genetics , Cell Survival , Cells, Cultured , Glycoproteins/genetics , Mice , Mice, Inbred C57BL , RNA, Messenger/analysis , Receptors, Peptide/genetics , Receptors, Peptide/physiology , Receptors, Transforming Growth Factor beta , Sex Differentiation , Testicular Hormones/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...